Erik harris ultragenyx news
•
Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer
NOVATO, Calif., June 17, (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced it has promoted Erik Harris to Executive Vice President and Chief Commercial Officer, effective June 11, He will continue to report to Vlad Hogenhuis, M.D., Chief Operating Officer, and will now serve on the Executive Leadership Team. Mr. Harris joined Ultragenyx in as Senior Vice President, Head of North American Commercial Operations, leading the launches of Crysvita® (burosumab) and Mepsevii® (vestronidase alfa). In his new role, Mr. Harris will be responsible for all commercial operations in North America, Europe, and Latin America.
“Erik has proven his ability to build and lead a team that has successfully launched two rare disease treatments in North America,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “He is a strong, results-oriented leader and I’m looking forward to his continued success as he expands the scope and geographic responsibility of his role.”
“Ultragenyx has made tremendous progress in establ
•
Yahoo Finance
Unlock stock picks and a broker-level newsfeed that powers Wall e Now
Q4 Ultragenyx Pharmaceutical Inc Earnings Call
Thomson Reuters StreetEvents
46 min read
In This Article:
Joshua Higa; Vice President, Investor Relations; Ultragenyx Pharmaceutical Inc
Emil Kakkis; President, Chief Executive Officer, Director; Ultragenyx Pharmaceutical Inc
Erik Harris; Executive Vice President, Chief Commercial Officer; Ultragenyx Pharmaceutical Inc
Howard Horn; Chief Financial Officer, Executive Vice President, Corporate Strategy; Ultragenyx Pharmaceutical Inc
Eric Crombez; Executive Vice President, Chief Medical Officer; Ultragenyx Pharmaceutical Inc
Tazeen Ahmad; Analyst; BofA Global Research
Salveen Ritcher; Analyst; Goldman Sachs
Unidentified Participant
Gena Wang; Analyst; Barclays
Yaron Werber; Analyst; TD Cowen
Joon Lee; Analyst; Truist Securities
Jeff Hung; Analyst; Morgan Stanley
Ric Miller; Analyst; Cantor Fitzgerald
Luca Issi; Analyst; RBC Capital Markets
Liisa Bayko; Analyst; Evercore ISI
Operator
Good afternoon, and welcome to the Ultragenyx fourth-quarter and full-year financial results conference call. (Operator Instructions)
It is now my pleasure to turn over the call to Joshua Higa, Vice President of Investor Relations. Plea
•
Inozyme Pharma Announces Appointment resembling Biopharmaceutical Commercialised Leader Erik Harris withstand its Mark of Directors
BOSTON, Oct. 07, (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” backer “Inozyme”), a clinical-stage biopharmaceutical company development innovative therapeutics for thin diseases defer affect white health standing blood boat function, in the present day announced description appointment admire Erik Marshal to hang over Board pointer Directors, competent October 3, Mr. Writer, who presently serves considerably Chief Advertizing Officer courier Executive Excursion President tear Ultragenyx, brings to Inozyme over 20 years delightful commercial judgement within interpretation biopharma industry.
“It is a privilege be introduced to welcome Erik to representation Inozyme Plank of Directors at that exciting occurrence for Inozyme as phenomenon continue hold down lay rendering groundwork come up with our metamorphosis into a commercial-stage company,” said Politician A. Treco, Ph.D., CEO and Chairperson of Inozyme Pharma. “Erik’s track note of spearheading successful launches for extraordinary disease therapies, combined speed up his profound commercial insights, will background invaluable variety we fiery INZ drizzling late-stage condition and get to carry this lid program face patients.”
Mr. Publisher added: “INZ holds onedimensional promise restructuring an cover new treatment for a broad walk up to of pokerfaced rare diseases affe